Israel - Ibrani - Ministry of Health

padagis israel pharmaceuticals ltd, israel - testosterone - ג'ל - testosterone 50 mg/dose - testosterone and estrogen - testosterone and estrogen - testosterone replacement therapy for males hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Israel - Ibrani - Ministry of Health

j-c health care ltd - golimumab - תמיסה להזרקה - golimumab 50 mg / 0.5 ml - golimumab - golimumab - rheumatoid arthritis :simponi, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis when the response to disease-modifying anti-rheumatic drug (dmard) therapy including mtx has been inadequate.psoriatic arthritis :simponi, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active and progressive psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate.ankylosing spondylitis :simponi is indicated for the treatment of adult patients with severe active ankylosing spondylitis who have responded inadequately to conventional therapy.

Israel - Ibrani - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - טבליות בשחרור מבוקר - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.

Israel - Ibrani - Ministry of Health

zoetis israel holding b.v., israel - ceftiofur hydrochloride - תרחיף להזרקה - ceftiofur hydrochloride 50 mg / 1 ml

Israel - Ibrani - Ministry of Health

zoetis israel holding b.v., israel - amoxicillin as trihydrate; clavulanic acid as potassium; prednisolone - תמיסה לאינפוזיה - amoxicillin as trihydrate 200 mg/dose; clavulanic acid as potassium 50 mg/dose; prednisolone 10 mg/dose - combinations

Israel - Ibrani - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - טבליות בשחרור מבוקר - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor

Israel - Ibrani - Ministry of Health

novartis israel ltd - glyceryl trinitrate - מדבקות - glyceryl trinitrate 50 mg/patch - glyceryl trinitrate

Israel - Ibrani - Ministry of Health

novartis pharma services ag - glyceryl trinitrate 50 mg/patch - patches - glyceryl trinitrate - prophylaxis of angina pectoris.

Israel - Ibrani - Ministry of Health

novartis pharma services ag - glyceryl trinitrate 50 mg/patch - patches - glyceryl trinitrate - prophylaxis of angina pectoris.

Israel - Ibrani - Ministry of Health

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation